Clinical Trial to Evaluate Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.

Also called NCT03318276

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 170 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03318276
Other papers using this trial's data
  • Efficacy and Safety of SID142 in Patients With Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Clinical Trial Clinical therapeutics, 2022-04 DOI, PubMed 35410753

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03318276. Randomized; triple masking; primary purpose treatment. Start 2017-02-20 (actual); primary completion 2018-10-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial to Evaluate Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease
Condition
Peripheral Arterial Disease
Intervention (Drug)
SID142
Intervention (Drug)
Rinexin® Tab
Lead sponsor
SK Chemicals Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03318276
Content hash
42ca0c96e1df976f88ae5a424234c20998bcb4fb5630ca00c0027bca64e7bfc7